Yu Lin, Yang Xue, Lei Hui-Ping, Hu Yue-Ting, Wu Ling-Nan, Zhou Shao-Yu, Jin Feng
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou Province, China.
Mol Neurobiol. 2025 Jul 15. doi: 10.1007/s12035-025-05162-3.
Alzheimer's disease (AD) is a major cause of dementia, a life-threatening condition for which there is currently no cure. Currently, the treatment of AD focuses on reducing the accumulation of amyloid β-protein (Aβ) and the phosphorylation of Tau proteins (Tau). However, simply reducing pathological features does not completely improve AD. Therefore, there is an urgent need to explore a target that regulates AD-related pathologies and highlights its potential as a novel therapeutic target. Recent studies suggest that oxidative stress, neuroinflammation, autophagy dysfunction, and energy metabolism alterations are associated with the development of AD. Reviewing previous data, we found that AMP-activated protein kinase (AMPK) not only acts as a cellular energy sensor to influence the progression of AD, but also activation of AMPK affects the pathologic processes above. In this review, we provide an update on activating the AMPK pathway with targeting in AD therapy. Finally, research has shown that compounds can activate the AMPK pathway to affect a series of cellular processes and improve AD. We propose that AMPK activation represents a paradigm-shifting strategy for AD therapy by simultaneously targeting multiple pathological cascades, although challenges in isoform-specific activation and brain delivery warrant further investigation.
阿尔茨海默病(AD)是痴呆症的主要病因,痴呆症是一种危及生命的疾病,目前尚无治愈方法。目前,AD的治疗重点在于减少淀粉样β蛋白(Aβ)的积累和Tau蛋白(Tau)的磷酸化。然而,仅仅减少病理特征并不能完全改善AD。因此,迫切需要探索一个调节AD相关病理的靶点,并突出其作为新型治疗靶点的潜力。最近的研究表明,氧化应激、神经炎症、自噬功能障碍和能量代谢改变与AD的发展有关。回顾以往的数据,我们发现AMP激活的蛋白激酶(AMPK)不仅作为细胞能量传感器影响AD的进展,而且AMPK的激活还会影响上述病理过程。在本综述中,我们提供了关于在AD治疗中靶向激活AMPK途径的最新进展。最后,研究表明化合物可以激活AMPK途径,影响一系列细胞过程并改善AD。我们提出,激活AMPK代表了一种通过同时靶向多个病理级联反应来治疗AD的范式转变策略,尽管在亚型特异性激活和脑内递送方面存在挑战,仍需进一步研究。